MedTrace Logo

Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)

NCT02511756 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-12-16

No results posted yet for this study

Summary

The primary objective of this study is to investigate the anti-angiogenic effect of bevacizumab measured by CTP as a predictive marker for efficacy measured by progression-free survival (PFS) in mCRC patients under first-line bevacizumab-containing, fluoropyrimidine-based chemotherapy

Conditions

Interventions

DEVICE

Computed tomography X-ray system

Contrast-enhanced computed tomography of liver metastases

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Patrick Veit-Haibach

    lead OTHER

Principal Investigators

  • Patrick Veit-Haibach, MD · University Hospital Zurich, Diagnostic and Interventional Radiology

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-12-31
Completion
2017-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02511756 on ClinicalTrials.gov